Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

類似資料

• Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major
  著者:: Pennell, Dudley J., 等
  出版事項: (2012)
• Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
  著者:: Aydinok, Yesim, 等
  出版事項: (2015)
• Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
  著者:: Taher, Ali T, 等
  出版事項: (2016)
• Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
  著者:: Taher, Ali T., 等
  出版事項: (2013)
• Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
  著者:: Taher, Ali T, 等
  出版事項: (2014)